Cellular Therapy
From the Journals
New data further support curability of myeloma
A study has found that a sizable share of transplant-eligible patients can expect to live as long as similar people in the general population.
Conference Coverage
ASH preview: Studies target CAR T-cell improvements
New studies highlight the role of CAR T-cell therapies in CLL, ALL, and DLBCL.
Conference Coverage
Scleroderma SCOT trial findings hold similar in lung disease
CHICAGO –
From the Journals
AML relapse after HSCT linked to potentially reversible immune changes
Epigenetic changes that weaken the immune response appear to allow leukemic cells to escape surveillance after stem cell transplant for AML.
News from the FDA/CDC
Ruxolitinib receives priority review for acute GVHD
Ruxolitinib is under review as a treatment for patients with acute graft-versus-host disease who have had an inadequate response to...
From the Journals
Older age predicts mortality after alloHCT in NHL, but not relapse
The researchers said older age was an independent risk factor for nonrelapse mortality.
News
Ablation plus transplant for severe scleroderma shows 11-year benefits
CHICAGO – Follow-up to 11 years of patients with severe scleroderma in a stem cell treatment trial documented long-term durability and safety.
From the Journals
First reported case of induced resistance to tisagenlecleucel
The CAR gene was unintentionally introduced into a single leukemic B cell during T-cell manufacturing.
From the Journals
Autologous fecal transplant restores microbiota after allo-HSCT
The therapy could help stave off graft-versus-host disease in stem cell transplant patients.
Conference Coverage
CAR T-cell studies dominate ongoing cellular therapy trials
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
Feature
NICE looks likely to reject use of Kymriah for DLBCL
The U.K. agency issued draft guidance recommending against use of tisagenlecleucel (Kymriah) a month after issuing similar guidance about...